Sanne de Bruin

79 Transfusion practice in the bleeding critically ill; an international online survey – The TRACE-2 Survey Coagulation products What is your threshold for administering fibrin- ogen in... 41. … a general population of non-massive- ly bleeding critically ill patients? (10^9 cells/L) 42. … traumatic non-massively bleeding criti- cally ill patients? (10^9 cells/L) 43. … upper gastrointestinal-tract non-mas- sively bleeding critically ill patients? (10^9 cells/L) 44. … post-cardiothoracic surgery non-mas- sively bleeding critically ill patients? (10^9 cells/L) 45. … obstetric non-massively bleeding critical- ly ill patients? (10^9 cells/L) 46. … non-massively bleeding critically ill patients suffering from sepsis and/or dis- seminated intravascular coagulation? (10^9 cells/L) 47. … non-massively bleeding critically ill patients on extracorporeal membrane oxygenation? (10^9 cells/L) 48. … non-massively bleeding critically ill patients suffering from a hemorrhagic stroke and/or traumatic brain injury? (10^9 cells/L) 49. What guides your use of tranexamic acid (TXA) in critically ill patients with non-mas- sive bleeding? a. I empirically administer TXA b. I administer TXA after viscoelastic testing (TEG/ROTEM) c. Other (please specify) Tranexamic-acid 50. Do you give tranexamic-acid in non-mas- sively bleeding critically ill patients who are considered… Always Most of the time Sometimes Never A general bleeding ICU population Traumatic bleeding Upper gastrointestinal tract bleeding Post-cardiothoracic surgery bleeding Obstetric bleeding Sepsis + bleeding Disseminated intravascular coagulation + bleeding Extracorporeal membrane oxygenation + bleeding Hemorrhagic stroke and/or traumatic brain injury + bleeding 3